Stocktoria
MYRIAD GENETICS INC MYGN
MYRIAD GENETICS INC (MYGN) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $824.5M at a -44.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.281 |
| Retained earnings / assets | -1.589 |
| EBIT / assets | -0.548 |
| Equity / liabilities | 1.087 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MYGN | MYRIAD GENETICS INC | 5/9 | -5.88 | — | -1.6% |
| NEOG | NEOGEN CORP | 4/9 | -0.23 | — | -2.7% |
| LNTH | Lantheus Holdings, Inc. | 4/9 | 4.61 | 30.6 | +0.5% |
| NTLA | Intellia Therapeutics, Inc. | 2/9 | -6.12 | — | +16.9% |
| TKNO | Alpha Teknova, Inc. | 5/9 | -1.59 | — | +7.4% |
| ICCC | IMMUCELL CORP /DE/ | 6/9 | 2.93 | — | +4.3% |
| NNNN | Anbio Biotechnology | 4/9 | — | 326.5 | — |
About MYRIAD GENETICS INC
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
FAQ
Is MYGN financially healthy?
MYRIAD GENETICS INC's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does MYGN pay a dividend?
No, MYRIAD GENETICS INC does not currently pay a dividend.
How profitable is MYGN?
In FY2025, MYRIAD GENETICS INC had a net margin of -44.4% and a return on equity of -99.4%.
Is MYGN overvalued or undervalued?
MYRIAD GENETICS INC trades at about 53.8× trailing earnings — above its 10-year norm (10-year range 16.0×–485.7×, median 23.6×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for MYGN?
The average Wall-Street price target for MYRIAD GENETICS INC is $6.25, about 93.5% above the recent price, from 8 analysts (consensus: hold).
Is MYGN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on MYRIAD GENETICS INC: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.